Antidepressants versus placebo for the treatment of bulimia nervosa: a systematic review

References

• Wolfe BE. Dimensions of response to antidepressant agents in bulimia nervosa: a review. Archives of Psychiatric Nursing 1995; 9: 111–121
   PubMedGoogle Scholar
• Russell GFM. Bulimia nervosa: an ominous variant of anorexia nervosa. Psychological Medicine 1979; 9: 429–448
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders3rd edn. American Psychiatric Press, Washington 1980
   Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders3rd edn. American Psychiatric Press, Washington 1987, Revised
   Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders4th edn. American Psychiatric Press, Washington 1994
   Google Scholar
• World Health Organization. The ICD‐10 classification of mental and behavioral disorders. Clinical descriptions and diagnostic guidelines. World Health Organization, Geneva 1992
   Google Scholar
• Cochrane collaboration handbook, CD Mulrow, AD Oxman. BMJ Publishing, London 1996, Available in the Cochrane Library [Database on Disk and CDROM]. The Cochrane Collaboration. Issue 3. Oxford: Updated Software, 1996
   Google Scholar
• Schultz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. Journal of the American Medical Association 1995; 273: 408–412
   PubMed Web of Science ®Google Scholar
• Buchan IE. Arcus Quickstat Biomedical for Windows. Research Solutions, Cambridge 1997
   Google Scholar
• DerSimonian R, Laird N. Meta‐analysis in clinical trials. Controlled Clinical Trials 1986; 7: 177–188
   PubMedGoogle Scholar
• Cook RJ, Sachett DL. The number needed to treat: a clinically useful measure of treatment effect. British Medical Journal 1995; 310: 452–454
   PubMed Web of Science ®Google Scholar
• Hedges LV, Olkin I. Statistical methods for meta‐analysis. Academic Press, San Diego 1985
   Google Scholar
• Cohen J. Statistical power for the behavioral sciences2nd edn. Lawrence Erlbaum, Hillsdale, NJ 1988
   Google Scholar
• Light RJ, Pillemer DB. Summing up: the science of reviewing research. Harvard University Press, Cambridge, MA 1984
   Google Scholar
• Rosenthal R. The ‐file drawer problem’ and the tolerance for null results. Psychological Bulletin 1979; 86: 638–641
   Web of Science ®Google Scholar
• Fluoxetine Bulimia Nervosa Collaborative Study Group (FBNCSG). Fluoxetine in the treatment of bulimia nervosa. A multicenter, placebo‐controlled, double‐blind trial. Archives of General Psychiatry 1992; 49: 139–147
   PubMedGoogle Scholar
• Goldstein DJ, Wilson MG, Thomson VL, Potvin JH, Rampey AH, Jr. Long‐term fluoxetine treatment of bulimia nervosa. British Journal of Psychiatry 1995; 166: 660–666
   PubMed Web of Science ®Google Scholar
• Mitchell JE, Pyle RL, Eckert ED, Hatukami D, Pomeroy C, Zimmerman R. A comparison study of antidepressants and structured intensive group psychotherapy in the treatment of bulimia nervosa. Archives of General Psychiatry 1990; 47: 149–157
   PubMed Web of Science ®Google Scholar
• Rothschild R, Quitkin HM, Quiktin FM, et al. A double‐blind placebo‐controlled comparison of phenelzine and imipramine in the treatment of bulimia in atypical depressives. International Journal of Eating Disorders 1994; 15: 1–9
   PubMed Web of Science ®Google Scholar
• Walsh BT, Hadigan CM, Devlin MJ, Gladis M, Roose SP. Long‐term outcome of antidepressant treatment for bulimia nervosa. American Journal of Psychiatry 1991; 148: 1206–1212
   PubMed Web of Science ®Google Scholar
• Agras WS, Dorian B, Kirkley BG, Arnow B, Bachman J. Imipramine in the treatment of bulimia: a double‐blind controlled study. International Journal of Eating Disorders 1987; 6: 29–38
   Web of Science ®Google Scholar
• Horne RL, Ferguson JM, Pope HG, Jr, et al. Treatment of bulimia with bupropion: a multicenter controlled trial. Journal of Clinical Psychiatry 1988; 49: 262–266
   PubMed Web of Science ®Google Scholar
• Mccann UD, Agras WS. Successful treatment of nonpurging bulimia nervosa with desipramine: a double‐blind, placebo‐controlled study. American Journal of Psychiatry 1990; 147: 1509–1513
   PubMed Web of Science ®Google Scholar
• Mitchell JE, Groat R. A placebo‐controlled double‐blind trial of amitriptyline in bulimia. Journal of Clinical Psychopharmacology 1984; 4: 186–193
   PubMed Web of Science ®Google Scholar
• Pope HG, Jr, Hudson JI, Jonas JM, Yurgelum‐Todd D. Bulimia treated with imipramine: a placebo‐controlled, double‐blind study. American Journal of Psychiatry 1983; 140: 554–558
   PubMed Web of Science ®Google Scholar
• Pope HG, Keck PE, Mcelroy S, Hudson JI. A placebo‐controlled study of trazodone in bulimia nervosa. Journal of Clinical Psychopharmacology 1989; 9: 254–259
   PubMed Web of Science ®Google Scholar
• Walsh BT, Gladis M, Roose SP, Stewart JW, Glassman AH. Phenelzine vs placebo in 50 patients with bulimia. Archives of General Psychiatry 1988; 45: 471–475
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Piran N, Warsh JJ, et al. A trial of isocarboxazid in the treatment of bulimia nervosa. Journal of Clinical Psychopharmacology 1988; 8: 391–396
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Goldbloom DS, Ralevski E, Davis C, D'souza JD, Lofchy J. Is there a role for selective monoamine oxidase inhibitor therapy in bulimia nervosa? A placebo‐controlled trial of braforamine. Journal of Clinical Psychopharmacology 1993; 13: 415–422
   PubMed Web of Science ®Google Scholar
• Sabine EJ, Yonace A, Farrington AJ, Barrant KH, Wakeling A. Bulimia nervosa: a placebo‐controlled double‐blind therapeutic trial of mianserin. British Journal of Clinical Pharmacology 1983; 15: 195–202
   Web of Science ®Google Scholar
• Kanerva R, Rissanen A, Sarna S. Fluoxetine in the treatment of anxiety, depressive symptoms, and eating‐related symptoms in bulimia nervosa. Nordic Journal of Psychiatry 1994; 49: 237–242
   Web of Science ®Google Scholar
• Corcos M, Flament M, Atger F, Jeammet P. Traitement pharmacologique de la bulimie. L'Encephale 1996; 22: 133–142
   PubMedGoogle Scholar
• Foreyt JP, Poston WSC, Goodrick GK. Future directions in obesity and eating disorders. Addictive Behaviours 1996; 21: 767–778
   PubMedGoogle Scholar
• Hsu LKG. Outcome of bulimia nervosa. Eating disorders and obesity. A comprehensive handbook, KD Browel, CG Fairburn. Guilford, New York 1995
   Google Scholar
• Shaw B, Garfinkel PE. Problems of research on eating disorders. International Journal of Eating Disorders 1990; 5: 545–555
   Google Scholar
• Wilson GT. Empirically validated treatments as a basis for clinical practice. Problems and prospects. Scientific standards of psychological practice: issues and recommendations, SC Hayes, VM Follette, T Risley, RD Dawes, K Grady. Context, Reno 1995; 163–196
   Google Scholar
• Bacaltchuk JB, Hay P, Trefiglio R, Mari JJ. Antidepressants versus psychotherapy for the treatment of bulimia nervosa. Paper presented at the Sixth International Cochrane Colloquium, Baltimore, Maryland, 1998
   Google Scholar
• Bacaltchuk JB, Trefiglio R, Oliveira IR, Lima MS, Mari JJ. Antidepressants versus psychotherapy for bulimia nervosa: a systematic review. Journal of Clinical Pharmacy and Therapeutics 1999; 24: 23–31
   PubMedGoogle Scholar
• Pyle RL, Mitchell JE, Eckert ED, Hatsukami D, Pomeroy C, Zimmerman R. Maintenance treatment and 6‐month outcome for bulimic patients who respond to initial treatment. American Journal of Psychiatry 1990; 147: 871–875
   PubMed Web of Science ®Google Scholar
• Fichter MM, Krüger R, Rief W, Holland RD, Döhne J. Fluvoxamine in prevention of relapse in bulimia nervosa: effects on eating specific psychopathology. Journal of Clinical Psychopharmacology 1996; 16: 9–18
   PubMed Web of Science ®Google Scholar
• Lima MS, Montcrieff J. A comparison of drugs versus placebo for the treatment of dysthymia: a systematic review (Cochrane review). The Cochrane Library. Update Software, Oxford 1998, Issue 2
   Google Scholar
• Mitchell JE, Specker SM, de Zwaan M. Comorbidity and medical complications of bulimia nervosa. Journal of Clinical Psychiatry 1991; 52: 13–20
   PubMedGoogle Scholar
• Hughes PL, Wells LA, Cunningham CJ, Ilstrup DM. Treating bulimia with desipramine. A double‐blind, placebo‐controlled study. Archives of General Psychiatry 1986; 43: 82–86
   Google Scholar
• Barlow J, Bloin J, Blouin A, Perez E. Treatment of bulimia with desipramine: a double‐blind crossover study. Canadian Journal of Psychiatry 1988; 33: 129–133
   PubMed Web of Science ®Google Scholar
• Blouin AG, Blouin JH, Perez EL, Bushnik T, Zuro C, Mulder E. Treatment of bulimia with fenfluramine and desipramine. Journal of Clinical Psychopharmacology 1988; 8: 261–269
   PubMed Web of Science ®Google Scholar
• Alger AS, Shwalberg MD, Bigaouette JM, Michalek AV, Howard LJ. Effect of a tricyclic antidepressant and opiate antagonist on binge‐eating behavior in normoweight bulimic and obese, binge‐eating subjects. American Journal of Clinical Nutrition 1991; 53: 865–871
   PubMed Web of Science ®Google Scholar
• Marcus MD, Wing RR, Ewing L, Kern E, Mcdermott M, Gooding W. A double‐blind placebo‐controlled trial of fluoxetine plus behavioral modification in the treatment of obese binge‐eaters. American Journal of Psychiatry 1990; 147: 876–881
   PubMed Web of Science ®Google Scholar
• Scrimali T, Grimali L, Corriere A, Grasso F, Frisone MF. La fluoxetina nel tratamento farmacologico della bulimia nervosa. Rivista Di Psichiatria 1994; 29: 171–177
   Google Scholar